Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Annual Information Update

15 Jan 2007 12:52

Phytopharm PLC15 January 2007 Phytopharm plc Annual Information Update Phytopharm plc (the Company) announces that, in accordance with the requirements of Prospectus Rule 5.2 issued by the Financial Services Authority, and following publication of the Annual Report on 28 December 2006, the following information has been published or made available to the public during the 12 months ended 12 January 2007, in compliance with laws and rules dealing with the regulation of securities, issuers of securities and securities markets. For the purpose of this update, only references to the information are provided. Full copies of each item can be found at the locations specified below. In accordance with the provisions of Article 27.3 of the Prospectus Directive Regulations, we confirm that to the best of our knowledge, information relating to 'Holdings in Company' and 'Director/PDMR Shareholdings' is up to date at the date of this announcement, but it is acknowledged that such disclosures may, at any time, become out of date, due to changing circumstances. 1. Announcements made via Regulatory Information Services All documents listed below were published via a regulatory information service on the dates indicated: Date of publication Title 10 January 2007 Director/PDMR shareholding10 January 2007 Director/PDMR shareholding 9 January 2007 Board changes19 December 2006 Notification of total voting rights10 November 2006 Director/PDMR shareholding 8 November 2006 Preliminary results for the year ended 31 August 2006 1 November 2006 Block listing interim review27 October 2006 Notification of results18 September 2006 Block listing interim review 5 September 2006 Board changes21 July 2006 Board appointment 5 June 2006 Board appointment19 May 2006 Holding(s) in company11 May 2006 Director/PDMR shareholding11 May 2006 Director/PDMR shareholding 8 May 2006 Interim results 3 May 2006 Block listing interim review27 April 2006 Holding(s) in company27 April 2006 Holding(s) in company26 April 2006 Advisor appointment24 April 2006 Product launch10 April 2006 Research update30 March 2006 Notice of results17 March 2006 Block listing interim review30 January 2006 Second price monitoring extension30 January 2006 Price monitoring extension24 January 2006 Results of AGM 2. Documents despatched to shareholders The following documents have been despatched by the Company to holders of its securities during the year: 27 December 2006 - Annual Report 2006 1 June 2006 - Interim Report 2006 3. Documents field at Companies House The Company has submitted the following Filings to Companies House: 11 January 2007 Form 288(a) Appointment of Director Mr Piers Morgan11 January 2007 Form 288(b) Terminating appointment of Director - Dr Richard Dixey 5 December 2006 Form 363 Annual Return 6 September 2006 Form 288(b) Terminating appointment of Director - Dr Trevor Flanagan 6 September 2006 Form 288(b) Terminating appointment of Director - Mr Gordon Stevens24 July 2006 Form 288(a) Appointment of Director - Dr Peter Blower 8 June 2006 Form 288(a) Appointment of Director - Mr Alexander Morrison24 January 2006 Registration of special resolutions passed at AGM Copies of these documents can be obtained from Companies House, Crown Way, Cardiff CF14 3UZ (Telephone 0870 3333 636, email at enquiries@companies-house.gov.uk) or, if you are a registered user, through Companies House Direct at www.companies-house.gov.uk The Company's annual report and accounts 2006 (published on 28 December 2006) and Interim Report 2005 (published on 1 June 2006) can be found on the Company's website as can the Interim Results announcement for the six months ended 28 February 2006 (published on 8 May 2006) and the Preliminary Results Announcement (published on 8 November 2006), The Company's website is www.phytopharm.com. Copies of all documents referred to above are also available for inspection at the Company's registered office (Corpus Christi House, 9 West Street, Godmanchester, Cambs PE29 2HY, United Kingdom) during normal business hours or by request from the Company Secretary. For further information, please contact: Zoe McGowan, Company Secretary Phytopharm plc Tel No: +44 (0)1480 437697 Further information, about Phytopharm can be found on the Company's website www.phytopharm.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
31st Jan 20234:35 pmRNSPrice Monitoring Extension
31st Jan 20232:05 pmRNSSecond Price Monitoring Extn
31st Jan 20232:00 pmRNSPrice Monitoring Extension
31st Jan 202311:05 amRNSSecond Price Monitoring Extn
31st Jan 202311:00 amRNSPrice Monitoring Extension
27th Jan 20231:00 pmRNSResult of AGM
3rd Jan 20237:00 amRNSTotal Voting Rights
22nd Dec 202212:18 pmRNSDirector Bed & ISA Dealing
13th Dec 20227:00 amRNSPDMR Exercise of Options
9th Dec 20229:05 amRNSContract Win
8th Dec 20223:34 pmRNSContract Update
7th Dec 20227:00 amRNSFinancial Results for the year ended 30 Sept 2022
21st Nov 20227:00 amRNSNotice of Results and Investor Presentation
25th Oct 20227:00 amRNSTrading Update
21st Sep 202210:35 amRNSHD-IH Consortium
14th Sep 20227:00 amRNSGrant of Share Options
1st Sep 20227:00 amRNSTrading Update and FY2023 Guidance
4th Aug 20227:00 amRNSContract Win
26th Jul 202211:22 amRNSContract Win - Replacement
21st Jul 20227:00 amRNSContract Win
14th Jun 20227:00 amRNSContract Extension
24th May 20227:00 amRNSHalf-year Report and Trading Update
16th May 20227:00 amRNSInvestor Presentation
10th May 20227:00 amRNSConsortium Agreement in Huntington's Disease
25th Apr 20227:00 amRNSTrading Update
21st Apr 20227:00 amRNSNew Contract Win
8th Mar 20227:00 amRNSContract worth circa £800k
14th Feb 20227:00 amRNSLaunch of IXIQ.Ai Deep learning AI-based platform
8th Feb 202212:30 pmRNSHolding(s) in Company
8th Feb 20227:00 amRNSContract award worth circa £1.0m
31st Jan 20227:00 amRNSAppointment of Senior Therapeutic Advisor
26th Jan 20227:00 amRNSDementia collaboration
21st Jan 20227:00 amRNSNon-Executive Director Appointment
20th Jan 202210:50 amRNSResult of AGM
20th Jan 20227:00 amRNSHuntington’s disease contract update
10th Jan 20227:00 amRNSGrant of share options
7th Dec 20217:00 amRNSFinancial Results for the year ended 30 Sept 2021
22nd Nov 20217:00 amRNSNotice of Results
1st Nov 20216:08 pmRNSHolding(s) in Company
1st Nov 20217:00 amRNSNew contract worth >£1.0m
20th Oct 20214:27 pmRNSContract update
18th Oct 20217:00 amRNSTrading Update for year ended 30 September 2021
22nd Sep 20217:00 amRNSNew contract worth >$750k
20th Sep 20217:00 amRNSPhase II HD contract with new client worth >$500K
8th Sep 20217:00 amRNSPhase I MSA contract award worth >$500k
6th Aug 20217:00 amRNSTrading Update
23rd Jun 20213:32 pmRNSIssue of Equity
21st Jun 20212:31 pmRNSHolding(s) in Company
15th Jun 20217:00 amRNSFurther investment in Ixico plc
11th Jun 202111:35 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.